Alexey is the Managing Partner and CEO of RBV Capital. He has over 20 years of experience in life sciences and pharma globally, and spent over 10 years in executive positions in early stage biotech-focused venture capital. Alexey previously served as an Investment Director at Bioprocess Capital Ventures, and Scientific Outreach Lead at Monsanto. He has extensive experience as a board member in a number of companies, including Retrosense Therapeutics (acquired by Allergan in 2016) and Bonti Inc (acquired by Allergan in 2018). Alexey graduated from MSU (1989) and holds a Ph.D. in molecular biology from the University Louis Pasteur, France (1998).